Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
Silo enters into commercial evaluation license agreement for next generation liposomes
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
Amarex Clinical Research guides its client to phase II of FDA trials
Efgartigimod is approved in the United States as VYVGART for the treatment of adults with generalized myasthenia gravis
Positive opinion could expand the role of Cosentyx (secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EU
It is developing the drug candidate to potentially treat immunological diseases
CLNK is a biotechnology research and development company that utilizes umbilical cord blood as the raw material to develop innovative, allogeneic, off-the-shelf, cell based therapeutic products
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
Subscribe To Our Newsletter & Stay Updated
